Nop30 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | O60936 |
Other Accession | NP_001171986, 8996 |
Reactivity | Human, Mouse, Rat |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | 22629 Da |
Application Notes | Nop30 antibody can be used for detection of Nop30 by Western blot at 0.5 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 0.5 μg/mL. |
Gene ID | 8996 |
---|---|
Other Names | Nop30 Antibody: ARC, FCM, MYP, NOP, NOP30, ARC, Nucleolar protein 3, Apoptosis repressor with CARD, Myp, nucleolar protein 3 (apoptosis repressor with CARD domain) |
Target/Specificity | Nop30 antibody was raised against a 14 amino acid synthetic peptide from near the carboxy terminus of human Nop30. The immunogen is located within the last 50 amino acids of Nop30. |
Reconstitution & Storage | Nop30 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Precautions | Nop30 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | NOL3 (HGNC:7869) |
---|---|
Function | [Isoform 1]: May be involved in RNA splicing. |
Cellular Location | [Isoform 1]: Nucleus, nucleolus. Note=The SR-rich C-terminus mediates nuclear localization. [Isoform 2]: Cytoplasm. Mitochondrion {ECO:0000250|UniProtKB:Q62881}. Sarcoplasmic reticulum {ECO:0000250|UniProtKB:Q62881}. Membrane; Lipid-anchor. Note=Phosphorylation at Thr-149 results in translocation to mitochondria. Colocalized with mitochondria in response to oxidative stress. {ECO:0000250|UniProtKB:Q62881} |
Tissue Location | Highly expressed in heart and skeletal muscle. Detected at low levels in placenta, liver, kidney and pancreas |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Nop30 Antibody: Apoptosis, also known as programmed cell death, plays major roles in development and normal tissue turnover in addition to tumor formation. Apoptosis is regulated by death domain (DD) and/or caspase recruitment domain (CARD) containing molecules and the caspase family of proteases. CARD domain containing cell death regulators include RAIDD, Apaf-1, caspase-9, and caspase-2. A novel CARD domain containing protein was recently identified and designated ARC for apoptosis repressor with CARD. An alternate splicing isoform of ARC was identified as Nop30. While ARC interacts with caspase-2 and -8 and suppresses apoptosis induced by cell death adapters FADD and TRADD and by cell death receptors Fas, TNFR-1 and DR3, Nop30 multimerizes and binds to the splicing factor SRp30c and may act to influence alternative splice site selection in vivo. The Nop30 antibody will not detect ARC protein.
References
Jin Z and El Deiry WS. Overview of cell death signaling pathways. Cancer Biol. Ther. 2004; 4:139-63.
Koseki T, Inohara N, Chen S, et al. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc. Natl. Acad. Sci. USA 1998; 95:5156-60.
Stoss O, Schwaiger FW, Cooper TA, et al. Alternative splicing determines the intracellular localization of the novel nuclear protein Nop30 and its interaction with the splicing factor SRp30c. J. Biol. Chem.1999; 274:10951-62
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.